Key Points
- Director Bros. Advisors LP Baker purchased 86,432 Kodiak Sciences shares at an average price of $98.51, for about $8.51 million. The purchase increased the director’s stake by 0.42% to 20,424,859 shares.
- Kodiak shares opened at $99.30, near their 52-week high of $104 and well above the 52-week low of $15.83.
- Analysts’ consensus rating is “Moderate Buy”, with an average price target of $104.71. In its latest reported quarter, Kodiak posted an adjusted loss of $1.05 per share, missing analysts’ $0.96 loss estimate.
Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) Director Bros. Advisors Lp Baker bought 86,432 shares of the stock in a transaction dated Thursday, November 5th. The stock was acquired at an average price of $98.51 per share, with a total value of $8,514,416.32. Following the completion of the purchase, the director owned 20,424,859 shares of the company's stock, valued at $2,012,052,860.09. This represents a 0.42% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Bros. Advisors Lp Baker also recently made the following trade(s):
- On Wednesday, November 4th, Bros. Advisors Lp Baker bought 160,658 shares of Kodiak Sciences stock. The shares were bought at an average price of $98.51 per share, with a total value of $15,826,419.58.
- On Monday, September 28th, Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock. The shares were purchased at an average cost of $72.57 per share, with a total value of $58,624,948.80.
- On Monday, September 28th, Bros. Advisors Lp Baker bought 418,323 shares of Kodiak Sciences stock. The stock was purchased at an average price of $83.58 per share, with a total value of $34,963,436.34.
- On Tuesday, September 29th, Bros. Advisors Lp Baker acquired 33,726 shares of Kodiak Sciences stock. The shares were bought at an average cost of $85.05 per share, with a total value of $2,868,396.30.
- On Monday, September 28th, Bros. Advisors Lp Baker bought 681,866 shares of Kodiak Sciences stock. The shares were bought at an average cost of $88.77 per share, for a total transaction of $60,529,244.82.
Kodiak Sciences Price Performance
Shares of NASDAQ:KOD opened at $99.30 on Friday. The firm has a market capitalization of $6.24 billion, a price-to-earnings ratio of -23.70 and a beta of 2.02. The business's 50 day moving average price is $69.56 and its 200-day moving average price is $43.69. Kodiak Sciences Inc. has a 1 year low of $15.83 and a 1 year high of $104.00.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). On average, sell-side analysts expect that Kodiak Sciences Inc. will post -3.97 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. increased its stake in shares of Kodiak Sciences by 72.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 60,256 shares of the company's stock valued at $5,712,000 after buying an additional 25,386 shares during the period. Pictet Asset Management Holding SA raised its stake in Kodiak Sciences by 20.0% during the third quarter. Pictet Asset Management Holding SA now owns 79,218 shares of the company's stock valued at $7,238,000 after purchasing an additional 13,203 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kodiak Sciences in the third quarter valued at $304,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Kodiak Sciences in the third quarter valued at approximately $664,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Kodiak Sciences by 15.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,468 shares of the company's stock valued at $1,045,000 after buying an additional 1,509 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several brokerages have weighed in on KOD. Wall Street Zen upgraded shares of Kodiak Sciences from a "strong sell" rating to a "sell" rating in a research note on Sunday, October 4th. UBS Group raised their price objective on shares of Kodiak Sciences from $80.00 to $120.00 and gave the stock a "buy" rating in a research report on Monday, September 28th. The Goldman Sachs Group began coverage on Kodiak Sciences in a report on Wednesday, September 30th. They set a "neutral" rating and a $103.00 target price on the stock. JPMorgan Chase & Co. increased their price target on Kodiak Sciences from $56.00 to $66.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. Finally, Jefferies Financial Group restated a "buy" rating and set a $112.00 target price on shares of Kodiak Sciences in a report on Monday, September 28th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Kodiak Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $104.71.
View Our Latest Stock Report on KOD
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc (NASDAQ: KOD) is a clinical-stage biopharmaceutical company focused on developing treatments for retinal diseases. The company's research centers on therapies designed to address conditions that can cause vision loss, including diabetic macular edema, neovascular age-related macular degeneration and retinal vein occlusion.
Kodiak's proprietary Antibody Biopolymer Conjugate platform is designed to combine the targeting capabilities of antibody-based medicines with a biodegradable polymer intended to extend the duration of treatment in the eye.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
